Post-allogeneic transplant Evans syndrome successfully treated with daratumumab

Richard Blennerhassett, Likhitha Sudini, David Gottlieb, Abir Bhattacharyya, Richard Blennerhassett, Likhitha Sudini, David Gottlieb, Abir Bhattacharyya

No abstract available

Keywords: ITP; immune haemolytic anaemia; transfusion medicine; transplantation.

References

    1. Chapuy, C.I., Kaufman, R.M., Alyea, E.P. & Connors, J.M. (2018) Daratumumab for delayed red-cell engraftment after allogeneic transplantation. New England Journal of Medicine, 379, 1846-1850.
    1. Cuker, A., Coles, A.J., Sullivan, H., Fox, E., Goldberg, M., Oyuela, P., Purvis, A., Beardsley, D.S. & Margolin, D.H. (2011) A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood, 118, 6299-6305.
    1. Dayan, C., Cuker, A., LaGanke, C., Fernandez, O., Hupperts, R.M.M., Sharrack, B., Singer, B., Vermersch, P., Margolin, D.H., Chou, E. & Twyman, C.L. (2016) Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis: 5-year follow-up of the CARE-MS studies. Multiple Sclerosis Journal, 22, 51-52.
    1. Marsh, J.C., Gupta, V., Lim, Z., Ho, A.Y., Ireland, R.M., Hayden, J., Potter, V., Koh, M.B., Islam, M.S., Russell, N., Marks, D.I., Mufti, G.J. & Pagliuca, A. (2011) Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood, 118, 2351-2357.
    1. Migdady, Y., Gupta, R., Ediriwickrema, A., Socola, F., Arai, S. & Martin, B.A. (2018) A case report of refractory immune thrombocytopenia (ITP) following reduced intensity conditioning (RIC) hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) successfully treated with off-label use of daratumumab. Blood, 132, 4976-4976.
    1. Ratnasingam, S., Walker, P.A., Tran, H., Kaplan, Z.S., McFadyen, J.D., Tran, H., Teh, T.C., Fleming, S., Catalano, J.V., Chunilal, S.D., Johnston, A., Opat, S.S. & Shortt, J. (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv, 1, 31-35.
    1. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.-L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of Bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
    1. Schuetz, C., Hoenig, M., Moshous, D., Weinstock, C., Castelle, M., Bendavid, M., Shimano, K., Tolbert, V., Schulz, A.S. & Dvorak, C.C. (2018) Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Advances, 2, 2550-2553.
    1. Seidel, M.G. (2014) Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood, 124, 2337-2344.
    1. Tolbert, V.P., Goldsby, R., Huang, J., Shimano, K., Melton, A., Willert, J., Horn, B.N., Dvorak, C.C. & Wahlstrom, J.T. (2016) Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report. Blood, 128, 4819-4819.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever